Premarket Decliner
INKT Mink Therapeutics17.50+3.30+23.2%
Premarket:14.80-2.70 (-15.4%)
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
Globe NewswireThu, 14-Aug 7:30 AM